These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21190159)

  • 1. Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy.
    Testino G; Borro P
    Hepatology; 2011 Apr; 53(4):1409-10. PubMed ID: 21190159
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis.
    Testino G; Sumberaz A; Ancarani AO; Borro P; Ravetti G; Ansaldi F; Andorno E; Gentile R; Icardi G
    Hepatogastroenterology; 2009; 56(90):501-3. PubMed ID: 19579629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
    Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
    Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
    J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.
    Testino G; Sumberaz A; Ravetti G; Gentile R; Ansaldi F; Icardi G
    Dig Liver Dis; 2006 Nov; 38(11):864-5. PubMed ID: 16945599
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
    Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
    Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
    Jian Wu Y; Shu Chen L; Gui Qiang W
    Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
    Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
    J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
    Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
    J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

  • 13. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Gholam PM
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682
    [No Abstract]   [Full Text] [Related]  

  • 14. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
    Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
    J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
    [No Abstract]   [Full Text] [Related]  

  • 15. [The study of optimal treatment in patients with refractory chronic hepatitis C].
    Chen XY; Zhang YH
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):488-9. PubMed ID: 19912679
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
    Kim SR; Saito J; Imoto S; Komaki T; Nagata Y; Nakajima T; Ando K; Fukuda K; Otono Y; Kim KI; Ohtani A; Sugimoto K; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Maekawa Y; Hayashi Y; Kudo M
    Digestion; 2011; 84 Suppl 1():5-9. PubMed ID: 22156479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A success story with chronic hepatitis C.
    Weekley D; Yuen JC
    J Ark Med Soc; 2005 Dec; 102(6):158-9. PubMed ID: 16381402
    [No Abstract]   [Full Text] [Related]  

  • 18. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
    Wedemeyer H; Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic hepatitis C virus infection.
    Flamm SL
    JAMA; 2003 May; 289(18):2413-7. PubMed ID: 12746366
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.
    Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Lenzi M; Bianchi FB
    Aliment Pharmacol Ther; 2005 Nov; 22(10):943-9. PubMed ID: 16268968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.